MedTrace Logo

Trial Designs for Evaluating Migraine Treatment

NCT06617832 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2026-04-13

No results posted yet for this study

Summary

The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, advanced balanced placebo design, patients with episodic migraine will receive six treatment conditions in a randomized order.

Conditions

  • Migraine With Aura
  • Migraine Without Aura
  • Headache, Migraine

Interventions

DRUG

Active drug for acute migraine treatment

Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine

DRUG

Placebo Oral Tablet

Inactive placebo pill (100 mg) looking like the active drug

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-13
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06617832 on ClinicalTrials.gov